Article Text

PDF
The efficacy of frequency specific microcurrent therapy on delayed onset hamstring muscle soreness
  1. D Curtis1,
  2. S Fallows1,
  3. M Morris1,
  4. C McMakin2
  1. 1Centre for Exercise & Nutrition Science, University of Chester, Chester, UK
  2. 2Fibromyalgia and Myofascial Pain Clinic of Portland, Portland, Oregon, USA

Abstract

Introduction The effects of frequency specific microcurrent (FSM) therapy versus sham therapy in delayed onset muscle soreness (DOMS) was studied to determine whether specific frequencies on two channels would produce better results than single channel single frequency microcurrent therapy which has been shown to be ineffective as compared to sham in DOMS. Frequency specific therapy is thought to operate by the effects of both microamperage current and resonance on tissues and biochemical bonds.

Methods 18 male and 17 female healthy participants (mean age 32 +/- 4.2 years) were recruited. Following a 15-minute treadmill warm-up and 5 sub-maximal eccentric muscle contractions, participants performed 5 sets of 15 maximal voluntary eccentric muscle contractions on a seated leg curl machine. Post-exercise, participants had one leg randomly assigned to a subsensory, silent treatment of 20 minutes of frequency specific microcurrent stimulation, while the other leg acted as non-treated control with the device turned off. (see figure 1) Participants were blinded to the treatment but the experimenter was not. Soreness was rated for each leg at baseline and at 24, 48 and 72 hours post exercise on a visual analogue scale (VAS), which ranged from 0 (no pain) to 10 (worst pain ever).

Figure 31

Frequency specific microcurrent stimulation

Results Both groups were identical at baseline (p = 1.00). Post-exercise there was a significant difference (p=0.0005) at 24 hours in the treated (1.3 / 10 ± 1.0) versus non-treated leg (5.2 / 10 ± 1.3). At 48 hours the treated leg was 1.2 / 10 ± 1.1 versus the non-treated of 7.0 / 10 ± 1.1 (p = 0.0005). At 72 hours the treated group was 0.7 / 10 ± 0.6 and the non-treated was 4.0 /10 ± 1.6 (p = 0.0005).

Conclusion FSM therapy provided significant protection from DOMS at all time points tested.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.